MYCi361 是一种MYC抑制剂，抑制肿瘤生长并增强 anti-PD1 免疫疗法，其与 MYC 结合的Kd为 3.2 μM。

MYCi361 is an inhibitor of MYC (binding to MYC with Kd of 3.2 μM).

MYCi361 is a small-molecule MYC inhibitors that inhibits the viability of MYC-dependent cancer cells including prostate cancer (MycCaP, LNCaP, and PC3), leukemia (MV4-11), lymphoma (HL-60 and P493-6), and neuroblastoma (SK-N-B2) with low-micromolar IC50 values[1].

MYC inhibitor 361 (MYCi361), suppressed in vivo tumor growth in mice, increased tumor immune cell infiltration, upregulated PD-L1 on tumors, and sensitized tumors to anti-PD1 immunotherapy.

FVB or NSG male mice of 6-8 weeks of age and 25 g bearing established MycCaP tumors.MYCi361 treatment i.p. initially at 50 mg/kg twice daily for 2 days, then 70 mg/kg/day for 9 days

2289690-31-7

C26H16ClF9N2O2

594.86

NUCC-0196361

DMSO:100 mg/mL (168.1 mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years